Citations

Institution: Mayo Clinic Clear

Showing 10 of 108083 citations.

Tumor-Associated Macrophages in Glioblastoma: Mechanisms of Tumor Progression and Therapeutic Strategies
Chen, Jianan , Wu, Qiong , Berglund, Anders , Macaulay, Robert , Mulé, James J. , Etame, Arnold B. , Berglund, Anders E , Macaulay, Robert J , Chen, Jianan , Etame, Arnold B

Cells | September 18, 2025 | Volume: 14 | Issue: 18 | Pages: 1458

10.3390/cells14181458 | PMID 41002423 Get It

Glioblastoma (GBM) is an aggressive brain tumor with a highly immunosuppressive microenvironment that promotes tumor progression and therapy resistance. Tumor-associated macrophages (TAMs), comprising up to 50% of the tumor mass, are recruited via chemokine axes such as CCL2/CCR2, CX3CL1/CX3CR1, and CXCL12/CXCR4 and adopt an M2-like immunosuppressive phenotype, facilitating immune escape and angiogenesis. Key signaling pathways, including CSF1R, STAT3, NF-κB, PI3K/Akt, and HIF-1α, regulate TAM function, making them promising therapeutic targets. Strategies such as TAM depletion, reprogramming, and immune checkpoint blockade (PD-1/PD-L1, and CD47-SIRPα) have shown potential in preclinical models. Emerging approaches, including CAR-macrophage (CAR-M) therapy, nanotechnology-based drug delivery, and exosome-mediated modulation, offer new avenues for intervention. However, clinical translation remains challenging due to GBM’s heterogeneity and adaptive resistance mechanisms. Future research should integrate multi-omics profiling and AI-driven drug discovery to refine TAM-targeted therapies and improve patient outcomes. This review provides a comprehensive analysis of TAM-mediated immune regulation in GBM and explores evolving therapeutic strategies aimed at overcoming its treatment barriers.
Evolution of Potentially Actionable Genomic Alterations in Advanced Prostate Cancer: A Real-World Analysis of Serial Circulating Tumor DNA Testing
Muniz, Miguel, Orme, Jacob J. , Wei, Nancy , Koch, Regina M. , Scharf, Zachary, Gupta, Sounak , Kase, Adam M. , Pessoa, Rodrigo Rodrigues, Kwon, Eugene D., Andrews, Jack R. , Muniz, Miguel , Orme, Jacob J , Basourakos, Spyridon P. , Wei, Nancy , Scharf, Zachary , Gupta, Sounak , Kase, Adam M , Childs, Daniel S , Tsai, Jill , Bucheit, Leslie , Riaz, Irbaz Bin , Childs, Daniel S.

Cancers | September 18, 2025 | Volume: 17 | Issue: 18 | Pages: 3048

10.3390/cancers17183048 | PMID 41008889 Get It

Background: Longitudinal genomic profiling through serial circulating tumor DNA (ctDNA) testing offers a noninvasive method to monitor clonal evolution in advanced prostate cancer. This study evaluated the frequency and nature of newly emergent and potentially actionable genomic alterations detected through serial testing in a real-world setting. Methods: We conducted a retrospective analysis of advanced prostate cancer patients who underwent multiple Guardant360 ctDNA tests between October 2020 and March 2023. The study focused on identifying new genomic alterations absent in the initial test, with particular attention to alterations relevant for on-label therapies, therapies approved in other oncologic indications (i.e., off-label), or a clinical trial. Results: Among 479 patients with at least two ctDNA tests, the median interval between the first and second evaluable tests was 207 days. New and potentially actionable alterations emerged in 57.8% of patients, including potential targets for on-label therapies (16.7%), off-label therapies (16.5%), and clinical trials (55.7%). Tumor mutational burden (TMB) increased from “low” to “high” in 11% of patients, although none had microsatellite instability or mismatch repair deficiency. In a Mayo Clinic subset, ten patients received olaparib based on treatment-emergent alterations, but none achieved a prostate-specific antigen (PSA) response. Two patients who transitioned from low to high TMB received pembrolizumab, both with progressive disease as best response. Conclusions: In a large real-world cohort, serial ctDNA testing frequently identified new alterations that were not detected at baseline and are potentially actionable therapeutic targets, highlighting the value of serial genomic profiling for capturing clonal dynamics. Additional research is needed to better establish a framework for retesting and to clarify how these results should influence subsequent treatment decisions.
A Multi‐Center Retrospective Cohort Study of Neurosarcoidosis Myelitis: Current Observations and Future Directions
Manzano, Giovanna S. , Balaban, Denis , Zhang, Yihan , Healy, Brian C. , Chwalisz, Bart K. , Levy, Michael , Venna, Nagagopal, Stern, Barney J. , Pardo, Carlos A. , Rjeily, Nicole Bou , Redenbaugh, Vyanka , Aksamit, Allen J. , Herman, Max Joseph, Rodriguez, Elsa, Snider, Laura, Rains, Hannah G , Montalvo, Mayra , Ramirez, Sergi Martinez, Horta, Lucas, Clardy, Stacey , Cho, Tracey , Samudralwar, Rohini, Torres, Noellie Rivera, Clifford, David B. , Majed, Masoud , Zabeti, Aram , Marcucci, Samuel , Mao‐Draayer, Yang , Doty, John D. , Agyei, Paunel, Bhattacharyya, Shamik , Berger, Joseph R. , Samudralwar, Rohini D , Dunham, S Richard , Levy, Michael , Clardy, Stacey L , Bhattacharyya, Shamik , Manzano, Giovanna Sophia , Balaban, Denis T , Cho, Tracey A , Pardo, Carlos A , Venna, Nagagopal , Barreras, Paula , Flanagan, Eoin P. , Hutto, Spencer K , Herman, Max, Sammak, Sally El , Snider, Laura, Rempe, Torge , Ramirez, Sergi Martinez, Lord, Jennifer, Abdel-Wahed, Lama , Torres, Noellie Rivera, Dunham, Steven , Doty, Jon

Annals of Clinical and Translational Neurology | September 18, 2025 | Volume: 12 | Issue: 12 | Pages: 2589-2599

10.1002/acn3.70200 | PMID 40963302 Get It

ABSTRACT Objective The optimal treatment for neurosarcoidosis myelitis is uncertain. We characterize incident neurosarcoidosis myelitis and assess treatment response by MRI and clinical scales. Methods Incident probable or definite neurosarcoidosis myelitis in adults was retrospectively identified from 13 academic medical centers. Cases were analyzed by initial treatment. The primary outcome was T1 post‐contrast gadolinium enhancement resolution at 6 months post‐treatment. Secondary outcomes were changes in modified Rankin scale (mRS) and Expanded Disability Status Scale (EDSS) from nadir to final follow‐up. Results Two hundred two patients were identified (median diagnosis age: 47 years (IQR 39–55); male: female 1.3:1). Median nadir mRS and EDSS were 2 (IQR 2–3) and 4 (IQR 2.5–6). At initial treatment, 129 (63.9%) received prolonged corticosteroids ≥ 4 weeks (group A 1 ), 36 (17.8%) received corticosteroids < 4 weeks (B 1 ), 21 (10.4%) received corticosteroids plus sarcoidosis‐directed immunosuppressant (E), and 16 (7.9%) received corticosteroids plus non‐sarcoidosis‐directed agents (F). In 167 cases with sufficient imaging, there were no significant differences in contrast enhancement resolution at 6 months (A 1 27/106 (25.5%), B 1 9/28 (32.1%), E 5/19 (26.3%), F 5/14 (35.7%); Fisher's exact p = 0.76). There were no significant differences in changes in mRS or EDSS among treatment groups (Kruskal–Wallis p = 0.69 and 0.63, respectively) after median follow‐up of 46.5 months (IQR 18–91.3). Interpretation Different initial immunosuppression strategies did not correlate with MRI contrast enhancement resolution at 6 months or clinical scales (mRS, EDSS). However, conclusions are limited by retrospective design, imbalanced cohorts, and insensitivity of binary MRI outcomes and available clinical scales for treatment response in neurosarcoidosis.
In Memoriam: Richard W. McCallum , MD , FACP , FRACP
Rao, Satish S.C. , Bharucha, Adil E. , Parkman, Henry P. , Saroseik, Irene, Parkman, H P , Rao, Satish , Mittal, Ravinder K.

Neurogastroenterology & Motility | September 18, 2025 | Volume: 37 | Issue: 12 | Pages: No page available

10.1111/nmo.70169 Get It

Efficacy of Montelukast–Antihistamine Combination Therapy Versus Antihistamine Monotherapy in Allergic Rhinitis: A Systematic Review and Meta-Analysis
Kim, Ji‐Sun , Stybayeva, Gulnaz , Hwang, Se Hwan , Stybayeya, Gulnaz , Hwang, Se Hwan

Clinical and Experimental Otorhinolaryngology | September 17, 2025 | Volume: 19 | Issue: 2 | Pages: 164-176

10.21053/ceo.2025-00201 | PMID 40961985 Get It

Objectives. Allergic rhinitis (AR) can substantially compromise daily functioning and well-being, and many patients require more than a single agent to obtain satisfactory symptom control. This study examined whether adding montelukast to antihistamine could manage AR symptoms and quality-of-life outcomes effectively.Methods. A review was performed in PubMed, Embase, Medline, Scopus, the Cochrane Library, and Google Scholar to identify eligible studies reported through April 2025. Eligible studies compared combination therapy with montelukast plus antihistamine against antihistamine monotherapy and reported nasal symptoms or rhinoconjunctivitis quality of life questionnaire (RQLQ) scores. Treatment effects were further examined by antihistamine class.Results. Fifteen studies including 2,882 subjects were analyzed. Combination therapy significantly improved daytime nasal symptoms (standardized mean difference [SMD] [95% CI], 0.44 [0.21–0.67]), nighttime nasal symptoms (0.12 [0.01–0.23]), and RQLQ scores (0.14 [0.00–0.27]) versus monotherapy. Individual nasal or ocular symptoms, sneezing, nasal obstruction, and rhinorrhea improved significantly, while nasal itching and ocular symptoms did not. Combinations with desloratadine and levocetirizine showed greater benefits than those with loratadine or fexofenadine.Conclusion. Montelukast–antihistamine combination therapy reduced overall symptoms and improved quality of life versus antihistamine monotherapy. The magnitude of benefit appears to vary depending on the specific antihistamine used, highlighting the possible value of individualized treatment strategies in the treatments of AR.
Quality measures for care of patients with restless legs syndrome: 2025 update after measure maintenance
Lloyd, Robin M. , Crawford, T’Auna, Donald, Ryan, Gray, Diedra D., Junna, Mithri R. , Lewin, Daniel , Revana, Amee , Schutte-Rodin, Sharon, Healy, William J.

Journal of Clinical Sleep Medicine | September 17, 2025 | Volume: 21 | Issue: 12 | Pages: 2205-2211

10.5664/jcsm.11894 | PMID 40958636 Get It

No Difference in Clinical Outcomes Between Concomitant Anterior and Posterior Cruciate Ligament Reconstruction With and Without Independent Suture Tape Augmentation
Tagliero, Adam J. , Cabarcas, Brandon C. , Iyer, Sanathan, Daniel, Adam V. , Kelly, John J., Krych, Aaron J. , Levy, Bruce A., Cabarcas, Brandon , Iyer, Sanathan , Krych, Aaron J , Tagliero, Adam , Iyer, Sanathan, Levy, Bruce A.

Arthroscopy, Sports Medicine, and Rehabilitation | September 17, 2025 | Volume: 7 | Issue: 6 | Pages: No page available

10.1016/j.asmr.2025.101261 | PMID 41541520 Get It

Purpose To compare clinical and functional outcomes (including range of motion, clinical laxity, reoperation/revision rates, and patient‐reported outcome measures) of combined anterior cruciate ligament/posterior cruciate ligament reconstruction (ACLR/PCLR) with and without suture tape (ST) augmentation via a propensity‐matched cohort analysis. Methods A retrospective review was performed to identify all patients who underwent simultaneous primary ACLR/PCLR between 2001 and 2022. A 1:1 propensity match was performed using patient sex, Schenck classification grade, age ±8 years, and body mass index ±10 to produce 2 cohorts: ACLR/PCLR with and without (control) ST augmentation. Clinical outcomes (visual analog scale [VAS], range of motion, Tegner activity scale, Lysholm score, and International Knee Documentation Committee subjective score) were analyzed. Results The propensity match produced a final cohort of 50 ACLR/PCLR patients: 25 with ST augmentation and 25 nonaugmented controls. Most patients had a KD3M injury (12 in each cohort), and no significant differences were noted in concomitant neurovascular, meniscal, or chondral injuries between the groups. Forty patients (80%) completed follow‐up at a mean of 4.7 years for the ST cohort and 8.5 years for the control cohort ( P > .05). Postoperative ST versus control values for outcome measures including VAS at rest (0.9 vs 1.5; P = .71), VAS with use (3.0 vs 2.2; P = .24), International Knee Documentation Committee (75.7 vs 76.3; P = .37), Lysholm (81.8 vs 77.6; P = .91), and Tegner activity (4.8 vs 5.4; P = .37) scores showed no differences ( P > .05 for all). There were no differences in excessive postoperative clinical laxity between ST and control cohorts (ST n = 1 vs control n = 2, Lachman 2+, P = .140; ST n = 3 vs control n = 1, posterior drawer 2+, P = .122). The total number of patients who underwent reoperation was 7 of 25 (28%) for the ST cohort and 8 of 25 (32%) for the control cohort ( P = .76). Conclusions Concomitant ACLR/PCLR utilizing ST augmentation showed similarly satisfactory postoperative clinical outcomes at a minimum 2‐year follow‐up compared to a matched cohort without ST. The use of an independent ST did not limit motion or increase the incidence of complications or revision surgery. Level of Evidence Level III, retrospective comparative case series.
A simple index for predicting mucus plugs in patients with chronic obstructive pulmonary disease
Wang, Wei , Borgaonkar, Ruchita , Mettler, S.K., Yen, Andrew , Grumley, Scott , Sonavane, Sushilkumar K. , Pistenmaa, Carrie L. , Estépar, Raúl San Jośe , Díaz, Alejandro A. , Mettler, Sofia K. , San Jose Estepar, Raul , Diaz, Alejandro A , Yen, Andrew, Nardelli, Pietro

American Journal of Respiratory and Critical Care Medicine | September 17, 2025 | Volume: 212 | Issue: 2 | Pages: 277-280

10.1164/rccm.202503-0563rl | PMID 40961266 Get It

Is there a place for deceased donor liver transplantation for colorectal metastases in the United States? Feasibility of a protocol utilizing machine perfusion
Jones, Jeremy , Taner, C. Burcin , O’Donnell, Connor, Inabinett, Samantha R, Boyle, Ashton, Majeed, Umair , Bolan, Candice W. , Toskish, Beau, Merchea, Amit , Harnois, Denise M. , Toskich, Beau B. , Fischer, Rebecca, Inabinett, Samantha, Majeed, Umair , Bolan, Candice, Toskich, Beau , Merchea, Amit , Harnois, Denise , Taner, Burcin , Jones, Jeremy C , O’Donnell, Connor, Fischer, Rebecca, Boyle, Ashton W.R. , Yang, Liu , Croome, Kristopher P.

Liver Transplantation | September 17, 2025 | Volume: 32 | Issue: 2 | Pages: 144-152

10.1097/lvt.0000000000000727 | PMID 40960762 Get It

Despite European colorectal liver metastases (CRLM) transplant trials having been performed entirely using deceased donor liver transplant (DDLT), there has been speculation about whether similar results can be achieved in the United States, given the lack of MELD score prioritization. A formal transplant protocol for unresectable CRLM was implemented in our center at the start of 2022 with the plan to utilize DDLT. Between 2022 and 2025, 86 patients with CRLM were referred to our program, and 19 patients underwent a formal transplant evaluation. Median time from listing until transplant was 31 days (range 3–115 d). Median allocation MELD was 8 (range 6–15). The donor livers were from DCDs, older donors, or National Share livers, which had been declined by all other centers. All but 2 of the cases underwent advanced perfusion. There were no cases of primary nonfunction, postreperfusion syndrome, acute kidney injury, hepatic artery thrombosis, or ischemic cholangiopathy. The length of stay for the median posttransplant was 5 days. Graft and patient survival were 100% at the time of maximal follow-up. Recurrence developed in 3 recipients (25.0%), 1 of whom was treated and has no evidence of disease. These findings support the viability of DDLT for CRLM using advanced perfusion, contingent on strict protocol adherence. Center-specific waitlist dynamics must inform the choice between DDLT and living donor liver transplant (LDLT).
Impact of Tricuspid Regurgitation on the Clinical Outcomes of Patients with Heart Failure
Almani, Muhammad Usman , Khan, Rasha , Yousuf, Muhammad , Amanullah, Aman, Fatima, Noor E

Public Health Challenges | September 17, 2025 | Volume: 4 | Issue: 3 | Pages: No page available

10.1002/puh2.70092 | PMID 40969311 Get It

ABSTRACTBackgroundTricuspid regurgitation (TR) is a common occurrence in patients with heart failure (HF), and its role in disease progression has gained attention in recent years. Although TR can worsen clinical outcomes in HF patients, the impact of gender, racial, and socioeconomic factors remains largely unexplored. With growing evidence supporting the role of percutaneous interventions for the treatment of significant TR, understanding these disparities is more crucial than ever.MethodsData were extracted from the National Inpatient and National Readmission 2016–2020 Databases. We used ICD‐10 code I50 to identify the patients primarily admitted for HF and subdivided the cohort into two groups based on the presence or absence of TR. We performed multivariable logistic regression analysis to determine odds of the in‐hospital mortality and multivariable Cox regression analysis to assess the 30‐ and 90‐day hospital readmission in HF patients with and without TR. All the analyses were adjusted for age, gender, insurance status, Charlson comorbidity index, and hospital characteristics. STATA 16 software was used for analysis.ResultsThere was no difference in the in‐hospital mortality among HF patients with and without TR (OR: 1.04, 95% CI 0.94–1.16, p = 0.442) except in certain subgroups of HF patients. HF patients with TR were 6% more likely to have HF‐specific readmission in 30 days (HR: 1.06, 95% CI 1.00–1.13, p = 0.044) and 9% more likely to have HF‐specific readmission in 90 days (HR: 1.09, 95% CI 1.03–1.15, p = 0.002). Subgroup analysis revealed significant gender, racial, and socioeconomic disparities in the in‐hospital mortality and the readmission outcomes of HF patients with TR compared to those without TR.ConclusionIn our population‐based survey analysis, we observed significant gender, racial, and socioeconomic disparities in the clinical outcomes of HF patients with TR compared to those without TR.